Format

Send to

Choose Destination
Mol Cancer Res. 2017 Apr;15(4):382-394. doi: 10.1158/1541-7786.MCR-16-0234. Epub 2017 Jan 20.

A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.

Author information

1
Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
2
Department of Obstetrics and Gynecology, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
3
Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
4
Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
5
Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. heide.ford@ucdenver.edu.

Abstract

TRAIL is a potent death-inducing ligand that mediates apoptosis through the extrinsic pathway and serves as an important endogenous tumor suppressor mechanism. Because tumor cells are often killed by TRAIL and normal cells are not, drugs that activate the TRAIL pathway have been thought to have potential clinical value. However, to date, most TRAIL-related clinical trials have largely failed due to the tumor cells having intrinsic or acquired resistance to TRAIL-induced apoptosis. Previous studies to identify resistance mechanisms have focused on targeted analysis of the canonical apoptosis pathway and other known regulators of TRAIL receptor signaling. To identify novel mechanisms of TRAIL resistance in an unbiased way, we performed a genome-wide shRNA screen for genes that regulate TRAIL sensitivity in sublines that had been selected for acquired TRAIL resistance. This screen identified previously unknown mediators of TRAIL resistance including angiotensin II receptor 2, Crk-like protein, T-Box Transcription Factor 2, and solute carrier family 26 member 2 (SLC26A2). SLC26A2 downregulates the TRAIL receptors, DR4 and DR5, and this downregulation is associated with resistance to TRAIL. Its expression is high in numerous tumor types compared with normal cells, and in breast cancer, SLC26A2 is associated with a significant decrease in relapse-free survival.Implication: Our results shed light on novel resistance mechanisms that could affect the efficacy of TRAIL agonist therapies and highlight the possibility of using these proteins as biomarkers to identify TRAIL-resistant tumors, or as potential therapeutic targets in combination with TRAIL. Mol Cancer Res; 15(4); 382-94. ©2017 AACR.

PMID:
28108622
PMCID:
PMC5380511
DOI:
10.1158/1541-7786.MCR-16-0234
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center